世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

デジタル薬局市場：医薬品（Rx、OTC）、製品（医療、パーソナルケア、ビタミン＆サプリメント、糖尿病、CVD、腫瘍）、プラットフォーム（アプリ、ウェブサイト）、ビジネスモデル（Captive、フランチャイズ、Aggregator）、地域（都市、地方）- 2027年までの世界市場予測


Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) - Global Forecasts to 2027

デジタルファーマシー市場は、2022年の965億米ドルから2027年には2119億米ドルに達し、予測期間中のCAGRは17.0%となる見通しです。この市場の成長は、COVID-19パンデミック時およびその後に、オンラインで医薬品... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2022年6月10日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		218 211 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

デジタルファーマシー市場は、2022年の965億米ドルから2027年には2119億米ドルに達し、予測期間中のCAGRは17.0%となる見通しです。この市場の成長は、COVID-19パンデミック時およびその後に、オンラインで医薬品を購入する消費者の嗜好が高まっていること、市場の統合やパートナーシップ、老年人口の増加などが要因となっています。
しかし、臨床支援を薬剤師に依存する患者や違法薬局の増加が、予測期間中の同市場の成長を抑制すると見られています。

「一般用医薬品（OTC）市場は予測期間中に最も高い成長率を示すと予想される
デジタルファーマシー市場は、薬剤の種類に基づき、処方箋医薬品と一般用医薬品に区分されます。2021年の世界のデジタルファーマシー市場では、処方箋医薬品が最大のシェアを占めています。この市場セグメントの大きなシェアは、いくつかの慢性疾患の有病率の増加や、それに伴う医薬品の需要の増加といった要因に起因するものです。
一方、店頭販売（OTC）製品セグメントは、予測期間中に最も高いCAGRで成長すると予想されます。この市場の成長は、一般用医薬品が広く入手可能で費用対効果に優れていること、またセルフメディケーションの傾向が強まっていることが主な要因となっています。


"2021年には医薬品・治療薬セグメントがtheDigital Pharmacy Marketの最大シェアを占めると予想"

デジタルファーマシー市場は、ofproducts（製品）ベースで、医薬品＆トリートメント、パーソナルケア製品、ビタミン＆サプリメント、その他製品に区分されます。2021年の世界のデジタルファーマシー市場では、医薬品・治療薬分野が最大のシェアを占めています。
しかし、ビタミン＆サプリメントセグメントは、慢性疾患の有病率の増加や複数の製品オプションの利用可能性から、予測期間中に最も高いCAGRを記録すると予想されます。



"プラットフォームにおけるアプリセグメントは、世界のデジタルファーマシー市場で最大のシェアを占めると予想される"
ofplatformsに基づいて、デジタルファーマシー市場は、アプリとウェブサイトに区分されます。2021年に、アプリは、世界のデジタル薬局市場の最大のシェアを保持すると予想され、このセグメントの成長はappsoffer有利なプロモや顧客を引き付けるために割引などの要因に起因する。Webサイトプラットフォームは、ウェブサイトが提供する便利さ、プライバシー、安全性が原因で予測期間中に2番目に高いCAGRで成長すると推定されている市場の成長を促進する重要な要因です。


"2021年の世界のデジタルファーマシー市場では、ビジネスモデルのうちキャプティブsegmentamongが最大のシェアを占めた"

デジタルファーマシー市場は、ofbusinessモデルに基づいて、キャプティブ、フランチャイズ、アグリゲータのビジネスモデルに区分されます。キャプティブビジネスモデルは、2021年に世界のデジタル薬局市場で最大のシェアを占め キャプティブビジネスモデルはまた、予測期間中に最高のCAGRを記録すると推定されます。キャプティブビジネスモデルの柔軟性、アクセス性、手頃な価格は、デジタルファーマシー市場のセグメント成長の主な要因です。アグリゲータービジネスモデルは、予測期間中に2番目に高いCAGRで成長すると推定されます。


"2021年、世界のデジタルファーマシー市場でUrbanareasaccounted the largest share"

地理的な範囲に基づいて、デジタルファーマシー市場は都市部と農村部に区分されます。都市部でのインターネットの普及が進んでいることから、2021年のデジタルファーマシー世界市場では、都市部が最大のシェアを占めています。

"予測期間中、北米がデジタルファーマシー市場を支配する"

2022年のデジタルファーマシー市場は、北米が最大のシェアを占めました。慢性疾患の蔓延、高齢化の急速な進展による薬剤処方数の増加、同地域における主要な市場プレイヤーの存在が、北米のデジタルファーマシー市場の成長を促進する主な要因となっています。
アジア太平洋地域は、疾病負担の増加、患者数の増加、医薬品市場の急成長により、予測期間中に最も高いCAGRを記録すると予測されます。


サプライサイドの一次面接の内訳（企業タイプ別、呼称別、地域別）。
- 企業タイプ別企業タイプ別：Tier 1 (41%)、Tier 2 (31%)、Tier 3 (28%)
- 役職別Cレベル(44%)、ディレクターレベル(35%)、その他(21%)
- 地域別北米 (46%)、欧州 (26%)、アジア太平洋 (18%)、中南米 (7%)、中東・アフリカ (3%)

本市場における主なプレイヤーは、CVS Health（米国）、Cigna（米国）、Optum, Inc.（UnitedHealth Group傘下）（米国）、Walgreens Co.（米国）、Walmart Inc.(米国）、Hims&Hers Health, Inc.（米国）、PharmEasy（インド）、Apollo Pharmacy（インド）、DocMorris（オランダ）、Giant Eagle Inc（米国）、LloydsPharmacy（英国）、Shop-apotheke.com（オランダ）、Tata 1mg（インド）、Netmeds.com（インド）、HealthWarecy.com（インド）、HealthWarehouse, Inc（米国）、Pharmex Direct Inc（カナダ）、Apex Pharmacy（英国）、TELUS（カナダ）、RO Pharmacy（米国）、Rx Outreach（米国）、The Independent Pharmacy（英国）、Rexall Pharmacy Group ULC（カナダ）、および NorthWestPharmacy.com （カナダ）これらの企業は、デジタル薬局市場における製品提供を拡大するために製品/サービスのアップグレード、買収、提携、合意、拡張、および協力にますます焦点を合わせています。

調査範囲
- 本レポートでは、薬剤の種類、製品、プラットフォーム、ビジネスモデル、地理的範囲、地域などに基づいてtheDigital Pharmacy市場を調査しています。
- 市場成長に影響を与える要因（ドライバー、阻害要因、機会、andchallengesなど）を分析しています。
- 利害関係者向けに市場の機会や課題を評価し、市場リーダー向けに競争環境の詳細を提供します。
- デジタルファーマシー市場全体に対する成長動向、展望、貢献度に関してミクロ市場を調査しています。
- 主要5地域に関する市場セグメントの売上高を予測しています。

レポート購入の主なメリット

本レポートは、市場全体とサブセグメントの収益数値の最も近い近似値に関する情報を提供し、この市場のリーダー/新規参入者を支援します。本レポートは、利害関係者が競争環境を理解し、より良いビジネスの位置づけと適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、本レポートは、関係者がデジタル薬局市場の鼓動を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供するのに役立ちます。

ページTOPに戻る


目次

1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.2.1 DIGITAL PHARMACY MARKET: INCLUSIONS & EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
FIGURE 1 DIGITAL PHARMACY MARKET 28
1.3.2 YEARS CONSIDERED FOR THE STUDY 29
1.4 CURRENCY 29
1.5 LIMITATIONS 29
1.5.1 SCOPE-RELATED LIMITATIONS 29
1.6 STAKEHOLDERS 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
FIGURE 2 RESEARCH DESIGN 30
2.1.1 SECONDARY DATA 31
2.1.1.1 Key data from secondary sources 32
2.1.2 PRIMARY RESEARCH 32
2.1.2.1 Key industry insights 33
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 34
2.2 MARKET ESTIMATION 34
2.2.1 APPROACH 1: SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 34
2.2.2 APPROACH: REVENUE MAPPING-BASED MARKET ESTIMATION 35
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 36
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36
FIGURE 6 REVENUE SHARE ANALYSIS ILLUSTRATION FOR CVS HEALTH 37
2.2.3 TOP-DOWN APPROACH: CONTRIBUTION-BASED MARKET SIZE ESTIMATION 38
FIGURE 7 DIGITAL PHARMACY MARKET: TOP-DOWN APPROACH 38
2.2.4 GROWTH FORECAST 38
FIGURE 8 IMPACT OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ON MARKET GROWTH & CAGR 39
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 39
2.3 MARKET DATA ESTIMATION AND TRIANGULATION 40
FIGURE 10 DATA TRIANGULATION METHODOLOGY 40
2.4 ASSUMPTIONS FOR THE STUDY 41
2.5 LIMITATIONS 41
2.6 RISK ASSESSMENT 42
TABLE 1 RISK ASSESSMENT: DIGITAL PHARMACY MARKET 42
3 EXECUTIVE SUMMARY 43
FIGURE 11 DIGITAL PHARMACY MARKET, BY DRUG TYPE, 2022 VS. 2027 (USD MILLION) 43
FIGURE 12 DIGITAL PHARMACY MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 44
FIGURE 13 DIGITAL PHARMACY MARKET, BY PLATFORM, 2022 VS. 2027 (USD MILLION) 44
FIGURE 14 DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2022 VS. 2027 (USD MILLION) 45
FIGURE 15 DIGITAL PHARMACY MARKET, BY GEOGRAPHIC COVERAGE,
2022 VS. 2027 (USD MILLION) 46
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE DIGITAL PHARMACY MARKET 47
4 PREMIUM INSIGHTS 48
4.1 DIGITAL PHARMACY MARKET OVERVIEW 48
FIGURE 17 GROWING GERIATRIC POPULATION TO DRIVE THE MARKET GROWTH 48
4.2 DIGITAL PHARMACY MARKET, BY PRODUCT 49
FIGURE 18 MEDICINES & TREATMENTS ACCOUNTED FOR THE LARGEST SHARE
OF THE DIGITAL PHARMACY MARKET IN 2021 49
4.3 NORTH AMERICA: DIGITAL PHARMACY MARKET, BY DRUG & COUNTRY (2021) 49
FIGURE 19 PRESCRIPTION MEDICINES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2021 49
4.4 GEOGRAPHICAL SNAPSHOT OF THE DIGITAL PHARMACY MARKET 50
FIGURE 20 ASIA PACIFIC MARKET TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 50
4.5 MARKET DYNAMICS 51
FIGURE 21 DIGITAL PHARMACY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 51
4.5.1 DRIVERS 52
4.5.1.1 Increasing consumer preference toward buying online medicines during and post the COVID-19 pandemic 52
TABLE 2 TOTAL NUMBER OF CONFIRMED CORONAVIRUS CASES, BY REGION
(AS OF JANUARY 7, 2022) 52
4.5.1.2 Consolidation in the market and partnerships 53
4.5.1.3 Growing geriatric population 53
TABLE 3 GLOBAL OVERVIEW OF THE RISE IN THE AGING POPULATION (MILLION) 53
4.5.2 RESTRAINTS 54
4.5.2.1 Growing number of illegal pharmacies 54
4.5.2.2 Risk of counterfeit drugs 54
4.5.2.3 Increased risk of drug abuse 55
4.5.3 OPPORTUNITIES 55
4.5.3.1 Emerging markets 55
4.5.3.2 Benefits of E-commerce 56
4.5.4 CHALLENGES 56
4.5.4.1 Challenges for patients relying on pharmacists for clinical support 56
4.5.4.2 Lack of strong national laws worldwide 57
4.5.4.3 Security and privacy concerns 58
4.6 VALUE CHAIN ANALYSIS 59
4.7 ECOSYSTEM ANALYSIS 60
4.8 PORTER’S FIVE FORCES ANALYSIS 60
TABLE 4 DIGITAL PHARMACY MARKET: PORTER’S FIVE FORCES ANALYSIS 60
4.8.1 INTENSITY OF COMPETITIVE RIVALRY 61
4.8.2 BARGAINING POWER OF SUPPLIERS 61
4.8.3 BARGAINING POWER OF BUYERS 61
4.8.4 THREAT FROM SUBSTITUTES 61
4.8.5 THREAT FROM NEW ENTRANTS 61
4.9 PRICING & REIMBURSEMENT ANALYSIS 61
TABLE 5 COMPARISON OF AVERAGE DISCOUNTED PRICES FOR A ONE-MONTH SUPPLY OF DRUGS 62
4.10 TECHNOLOGY ANALYSIS 62
4.10.1 MACHINE LEARNING 62
4.10.2 INTERNET OF THINGS 63
4.10.3 BLOCKCHAIN 63
4.10.4 CLOUD COMPUTING 63
4.11 INDUSTRY TRENDS 63
4.11.1 ONLINE PRESCRIPTION REFILL 63
4.11.2 VIRTUAL HEALTHCARE SERVICES 64
4.11.3 DIGITAL HEALTH DIAGNOSTIC TOOLS 64
4.12 KEY CONFERENCES & EVENTS IN 2021–2022 65
4.13 REGULATORY ANALYSIS 65
4.13.1 NORTH AMERICA 65
4.13.1.1 US 65
4.13.1.2 Canada 66
4.13.2 EUROPE 66
4.13.3 ASIA PACIFIC 67
4.13.4 REST OF THE WORLD 67
TABLE 6 APPROACHES OF REGULATORY AUTHORITIES (RA) WORLDWIDE
TO CONTROL MEDICINAL PRODUCT ONLINE SALES 67
4.14 CASE STUDIES 68
4.14.1 MAGENTO 2 WEB APP MODERNIZATION 68
4.14.1.1 Use Case 1: Need to Revamp Online Store 68
4.14.2 WALMART REACT NATIVE PHARMACY 69
4.14.2.1 Use Case 2: Need to Rebuild Pharmacy App 69
4.15 IMPACT OF COVID-19 ON THE DIGITAL PHARMACY MARKET 69
 
5 DIGITAL PHARMACY MARKET, BY DRUG TYPE 70
5.1 INTRODUCTION 71
TABLE 7 DIGITAL PHARMACY MARKET, BY DRUG TYPE, 2020–2027 (USD MILLION) 71
5.2 PRESCRIPTION MEDICINES 71
5.2.1 GROWING GERIATRIC POPULATION AND SUBSEQUENT INCREASE IN CHRONIC DISEASES TO DRIVE THE DEMAND FOR PRESCRIPTION MEDICATION 71
TABLE 8 DIGITAL PHARMACY MARKET FOR PRESCRIPTION MEDICINES, BY REGION, 2020–2027 (USD MILLION) 72
TABLE 9 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR PRESCRIPTION MEDICINES, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 10 EUROPE: DIGITAL PHARMACY MARKET FOR PRESCRIPTION MEDICINES,
BY COUNTRY, 2020–2027 (USD MILLION) 73
5.3 OVER-THE-COUNTER PRODUCTS 73
5.3.1 EASE OF USE AND CONVENIENCE ASSOCIATED WITH OVER-THE-COUNTER PRODUCTS TO DRIVE MARKET GROWTH 73
TABLE 11 DIGITAL PHARMACY MARKET FOR OVER-THE-COUNTER PRODUCTS,
BY REGION, 2020–2027 (USD MILLION) 74
TABLE 12 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR OVER-THE-COUNTER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 74
TABLE 13 EUROPE: DIGITAL PHARMACY MARKET FOR OVER-THE-COUNTER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 75
6 DIGITAL PHARMACY MARKET, BY PRODUCT 76
6.1 INTRODUCTION 77
TABLE 14 DIGITAL PHARMACY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 77
6.2 MEDICINES & TREATMENTS 77
TABLE 15 DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY REGION, 2020–2027 (USD MILLION) 78
TABLE 16 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 17 EUROPE: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 18 ASIA PACIFIC: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 19 DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY TYPE, 2020–2027 (USD MILLION) 79
6.2.1 DIABETES CARE 79
6.2.1.1 Growing global diabetic population will ensure strong demand for diabetes care medicines & treatments 79
TABLE 20 DIGITAL PHARMACY MARKET FOR DIABETES CARE MEDICINES & TREATMENTS, BY REGION, 2020–2027 (USD MILLION) 80
6.2.2 HEART CARE 80
6.2.2.1 Rising incidence of cardiovascular diseases drives the demand for heart care medicines & treatments 80
TABLE 21 DIGITAL PHARMACY MARKET FOR HEART CARE MEDICINES & TREATMENTS, BY REGION, 2020–2027 (USD MILLION) 81
6.2.3 ONCOLOGY 81
6.2.3.1 Increasing prevalence of cancer is a major factor driving the growth of this market segment 81
TABLE 22 DIGITAL PHARMACY MARKET FOR ONCOLOGY MEDICINES & TREATMENTS, BY REGION, 2020–2027 (USD MILLION) 81
6.2.3.2 Other medicines & treatments 82
TABLE 23 DIGITAL PHARMACY MARKET FOR OTHER MEDICINES & TREATMENTS,
BY REGION, 2020–2027 (USD MILLION) 82
6.3 PERSONAL CARE PRODUCTS 82
6.3.1 GROWING FOCUS ON PERSONAL HEALTH & HYGIENE TO DRIVE MARKET GROWTH 82
TABLE 24 DIGITAL PHARMACY MARKET FOR PERSONAL CARE PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 25 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR PERSONAL CARE PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 26 EUROPE: DIGITAL PHARMACY MARKET FOR PERSONAL CARE PRODUCTS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 27 ASIA PACIFIC: DIGITAL PHARMACY MARKET FOR PERSONAL CARE PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 VITAMINS & SUPPLEMENTS 84
6.4.1 GROWING DEMAND FOR IMMUNITY-ASSOCIATED SUPPLEMENTS IN THE WAKE OF THE COVID-19 PANDEMIC TO DRIVE MARKET GROWTH 84
TABLE 28 DIGITAL PHARMACY MARKET FOR VITAMINS & SUPPLEMENTS, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 29 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR VITAMINS & SUPPLEMENTS, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 30 EUROPE: DIGITAL PHARMACY MARKET FOR VITAMINS & SUPPLEMENTS,
BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 31 ASIA PACIFIC: DIGITAL PHARMACY MARKET FOR VITAMINS & SUPPLEMENTS, BY COUNTRY, 2020–2027 (USD MILLION) 86
6.5 OTHER PRODUCTS 86
TABLE 32 DIGITAL PHARMACY MARKET FOR OTHER PRODUCTS, BY REGION,
2020–2027 (USD MILLION) 86
TABLE 33 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 34 EUROPE: DIGITAL PHARMACY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 35 ASIA PACIFIC: DIGITAL PHARMACY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2020–2027 (USD MILLION) 87
7 DIGITAL PHARMACY MARKET, BY PLATFORM 88
7.1 INTRODUCTION 89
TABLE 36 DIGITAL PHARMACY MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 89
7.2 APPS 89
7.2.1 ADVANTAGES SUCH AS CONTACTLESS DELIVERY WILL
DRIVE THE DEMAND FOR APPS 89
TABLE 37 DIGITAL PHARMACY APPS MARKET, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 38 NORTH AMERICA: DIGITAL PHARMACY APPS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 90
TABLE 39 EUROPE: DIGITAL PHARMACY APPS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 90
TABLE 40 ASIA PACIFIC: DIGITAL PHARMACY APPS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 91
7.3 WEBSITES 91
7.3.1 PROMOTIONS, DISCOUNTS, AND OFFERS PROVIDED BY WEBSITES TO DRIVE MARKET GROWTH 91
TABLE 41 DIGITAL PHARMACY WEBSITES MARKET, BY REGION,
2020–2027 (USD MILLION) 92
TABLE 42 NORTH AMERICA: DIGITAL PHARMACY WEBSITES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 43 EUROPE: DIGITAL PHARMACY WEBSITES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 92
TABLE 44 ASIA PACIFIC: DIGITAL PHARMACY WEBSITES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 93
8 DIGITAL PHARMACY MARKET, BY BUSINESS MODEL 94
8.1 INTRODUCTION 95
TABLE 45 DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 95
8.2 CAPTIVE 95
8.2.1 FLEXIBILITY, ACCESSIBILITY, AND AFFORDABILITY OF CAPTIVE MODELS—
KEY FACTORS DRIVING MARKET GROWTH 95
TABLE 46 DIGITAL PHARMACY MARKET FOR CAPTIVE MODELS, BY REGION, 2020–2027 (USD MILLION) 96
TABLE 47 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR CAPTIVE MODELS,
BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 48 EUROPE: DIGITAL PHARMACY MARKET FOR CAPTIVE MODELS, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 49 ASIA PACIFIC: DIGITAL PHARMACY MARKET FOR CAPTIVE MODELS,
BY COUNTRY, 2020–2027 (USD MILLION) 97
8.3 FRANCHISE 97
8.3.1 GROWING NUMBER OF PHARMACY FRANCHISES TO DRIVE MARKET GROWTH 97
TABLE 50 DIGITAL PHARMACY MARKET FOR FRANCHISE MODELS, BY REGION,
2020–2027 (USD MILLION) 98
TABLE 51 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR FRANCHISE MODELS,
BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 52 EUROPE: DIGITAL PHARMACY MARKET FOR FRANCHISE MODELS,
BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 53 ASIA PACIFIC: DIGITAL PHARMACY MARKET FOR FRANCHISE MODELS,
BY COUNTRY, 2020–2027 (USD MILLION) 99
8.4 AGGREGATOR 99
8.4.1 QUALITY SERVICES ASSOCIATED WITH AGGREGATOR MODELS TO DRIVE MARKET GROWTH 99
TABLE 54 DIGITAL PHARMACY MARKET FOR AGGREGATOR MODELS, BY REGION, 2020–2027 (USD MILLION) 100
TABLE 55 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR AGGREGATOR MODELS, BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 56 EUROPE: DIGITAL PHARMACY MARKET FOR AGGREGATOR MODELS,
BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 57 ASIA PACIFIC: DIGITAL PHARMACY MARKET FOR AGGREGATOR MODELS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
9 DIGITAL PHARMACY MARKET, BY GEOGRAPHIC COVERAGE 102
9.1 INTRODUCTION 103
TABLE 58 DIGITAL PHARMACY MARKET, BY GEOGRAPHIC COVERAGE,
2020–2027 (USD MILLION) 103
9.2 URBAN AREAS 103
9.2.1 RAPID INTERNET PENETRATION IN URBAN AREAS TO DRIVE MARKET GROWTH IN THIS SEGMENT 103
TABLE 59 DIGITAL PHARMACY MARKET IN URBAN AREAS, BY REGION,
2020–2027 (USD MILLION) 104
9.3 RURAL AREAS 104
9.3.1 GOVERNMENT INITIATIVES TO FUEL THE DEMAND FOR DIGITAL PHARMACIES IN RURAL AREAS 104
TABLE 60 DIGITAL PHARMACY MARKET IN RURAL AREAS, BY REGION,
2020–2027 (USD MILLION) 105
10 DIGITAL PHARMACY MARKET, BY REGION 106
10.1 INTRODUCTION 107
TABLE 61 DIGITAL PHARMACY MARKET, BY REGION, 2020–2027 (USD MILLION) 107
10.2 NORTH AMERICA 107
10.2.1 IMPACT OF COVID-19 ON THE NORTH AMERICAN DIGITAL
PHARMACY MARKET 107
FIGURE 22 NORTH AMERICA: DIGITAL PHARMACY MARKET SNAPSHOT 108
TABLE 62 NORTH AMERICA: DIGITAL PHARMACY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 109
TABLE 63 NORTH AMERICA: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 109
TABLE 64 NORTH AMERICA: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 109
TABLE 65 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY TYPE, 2020–2027 (USD MILLION) 110
TABLE 66 NORTH AMERICA: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 110
TABLE 67 NORTH AMERICA: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL, 2020–2027 (USD MILLION) 110
TABLE 68 NORTH AMERICA: DIGITAL PHARMACY MARKET, BY GEOGRAPHIC COVERAGE, 2020–2027 (USD MILLION) 111
10.2.2 US 111
10.2.2.1 The US is the largest regional market for digital pharmacy, mainly due to the rising prevalence of chronic conditions and the growing number of prescriptions 111
TABLE 69 US: KEY MACROINDICATORS 112
TABLE 70 US: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 112
TABLE 71 US: DIGITAL PHARMACY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 112
TABLE 72 US: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY TYPE, 2020–2027 (USD MILLION) 113
TABLE 73 US: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 113
TABLE 74 US: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 113
TABLE 75 US: DIGITAL PHARMACY MARKET, BY GEOGRAPHIC COVERAGE,
2020–2027 (USD MILLION) 114
10.2.3 CANADA 114
10.2.3.1 Rising drug expenditures to propel market growth in Canada 114
TABLE 76 CANADA: KEY MACROINDICATORS 115
TABLE 77 CANADA: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 115
TABLE 78 CANADA: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 116
TABLE 79 CANADA: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 80 CANADA: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 116
TABLE 81 CANADA: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 117
TABLE 82 CANADA: DIGITAL PHARMACY MARKET, BY GEOGRAPHIC COVERAGE,
2020–2027 (USD MILLION) 117
10.3 EUROPE 117
10.3.1 IMPACT OF COVID-19 ON THE EUROPEAN DIGITAL PHARMACY MARKET 118
TABLE 83 EUROPE: DIGITAL PHARMACY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 118
TABLE 84 EUROPE: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 118
TABLE 85 EUROPE: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 119
TABLE 86 EUROPE: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY TYPE, 2020–2027 (USD MILLION) 119
TABLE 87 EUROPE: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 119
TABLE 88 EUROPE: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 120
10.3.2 GERMANY 120
10.3.2.1 Germany is the fastest-growing market for digital pharmacies in Europe 120
TABLE 89 GERMANY: KEY MACROINDICATORS 121
TABLE 90 GERMANY: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 121
TABLE 91 GERMANY: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 121
TABLE 92 GERMANY: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY TYPE, 2020–2027 (USD MILLION) 122
TABLE 93 GERMANY: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 122
TABLE 94 GERMANY: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 122
10.3.3 UK 123
10.3.3.1 Rising initiatives to improve the safety of digital pharmacies to boost the market growth 123
TABLE 95 UK: KEY MACROINDICATORS 124
TABLE 96 UK: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 124
TABLE 97 UK: DIGITAL PHARMACY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 124
TABLE 98 UK: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 99 UK: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 125
TABLE 100 UK: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 125
10.3.4 FRANCE 126
10.3.4.1 Rising geriatric population in the country to support market growth 126
TABLE 101 FRANCE: KEY MACROINDICATORS 126
TABLE 102 FRANCE: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 126
TABLE 103 FRANCE: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 127
TABLE 104 FRANCE: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 105 FRANCE: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 127
TABLE 106 FRANCE: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 128
10.3.5 ITALY 128
10.3.5.1 Growing burden of chronic diseases is driving the market
growth in Italy 128
TABLE 107 ITALY: KEY MACROINDICATORS 129
TABLE 108 ITALY: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 129
TABLE 109 ITALY: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 129
TABLE 110 ITALY: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 111 ITALY: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 130
TABLE 112 ITALY: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 130
10.3.6 SPAIN 131
10.3.6.1 Increasing focus on improving the healthcare infrastructure in the country to support market growth 131
TABLE 113 SPAIN: KEY MACROINDICATORS 131
TABLE 114 SPAIN: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 132
TABLE 115 SPAIN: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 132
TABLE 116 SPAIN: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 117 SPAIN: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 133
TABLE 118 SPAIN: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 133
10.3.7 ROE 133
TABLE 119 ROE: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 134
TABLE 120 ROE: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 134
TABLE 121 ROE: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY TYPE, 2020–2027 (USD MILLION) 135
TABLE 122 ROE: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 135
TABLE 123 ROE: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 135
10.4 ASIA PACIFIC 136
10.4.1 IMPACT OF COVID-19 ON THE ASIA PACIFIC DIGITAL PHARMACY MARKET 136
FIGURE 23 ASIA PACIFIC: DIGITAL PHARMACY MARKET SNAPSHOT 137
TABLE 124 ASIA PACIFIC: DIGITAL PHARMACY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 138
TABLE 125 ASIA PACIFIC: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 138
TABLE 126 ASIA PACIFIC: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 138
TABLE 127 ASIA PACIFIC: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 139
10.4.2 CHINA 139
10.4.2.1 Increasing consumer demand for OTC products to drive the market for digital pharmacy in China 139
TABLE 128 CHINA: KEY MACROINDICATORS 140
TABLE 129 CHINA: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 140
TABLE 130 CHINA: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 140
TABLE 131 CHINA: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 141
10.4.3 JAPAN 141
10.4.3.1 Rising healthcare expenditures and the growing burden of non-communicable diseases (NCDs) to drive market growth in Japan 141
TABLE 132 JAPAN: KEY MACROINDICATORS 142
TABLE 133 JAPAN: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 142
TABLE 134 JAPAN: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 142
TABLE 135 JAPAN: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 143
10.4.4 INDIA 143
10.4.4.1 Favorable government initiatives and high density of rural population to support market growth in India 143
TABLE 136 INDIA: KEY MACROINDICATORS 144
TABLE 137 INDIA: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 144
TABLE 138 INDIA: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 144
TABLE 139 INDIA: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY TYPE, 2020–2027 (USD MILLION) 145
TABLE 140 INDIA: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 145
TABLE 141 INDIA: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 145
10.4.5 REST OF ASIA PACIFIC 146
TABLE 142 ROAPAC: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 146
TABLE 143 ROAPAC: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 147
TABLE 144 ROAPAC: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 147
TABLE 145 ROAPAC: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 147
10.5 LATIN AMERICA 148
10.5.1 GROWING INTERNET USERS WILL FAVOR MARKET GROWTH IN LATAM 148
10.5.1.1 Impact of COVID-19 on the Latin American digital pharmacy market 148
TABLE 146 LATIN AMERICA: KEY MACROINDICATORS 149
TABLE 147 LATIN AMERICA: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 149
TABLE 148 LATIN AMERICA: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 149
TABLE 149 LATIN AMERICA: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 150 LATIN AMERICA: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 150
TABLE 151 LATIN AMERICA: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 150
10.6 MIDDLE EAST & AFRICA 151
10.6.1 INCREASING DEMAND FOR ONLINE PHARMACEUTICAL PRODUCTS WILL DRIVE THE MARKET IN THE MEA 151
10.6.1.1 Impact of COVID-19 on the Middle East & Africa digital
pharmacy market 152
TABLE 152 MEA: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 152
TABLE 153 MEA: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 152
TABLE 154 MEA: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY TYPE, 2020–2027 (USD MILLION) 153
TABLE 155 MEA: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 153
TABLE 156 MEA: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 153
11 COMPETITIVE LANDSCAPE 154
11.1 OVERVIEW 154
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 154
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN
THE DIGITAL PHARMACY MARKET 154
11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 155
11.4 MARKET RANKING 156
FIGURE 24 US DIGITAL PHARMACY MARKET RANKING, BY KEY PLAYER, 2021 156
11.5 COMPETITIVE BENCHMARKING 157
11.5.1 OVERALL COMPANY FOOTPRINT 157
TABLE 157 OVERALL COMPANY FOOTPRINT 157
11.5.2 COMPANY DRUG TYPE FOOTPRINT 157
TABLE 158 COMPANY DRUG TYPE FOOTPRINT 157
11.5.3 COMPANY PRODUCT FOOTPRINT 158
TABLE 159 COMPANY PRODUCT FOOTPRINT 158
11.5.4 COMPANY PLATFORM FOOTPRINT 158
TABLE 160 COMPANY PLATFORM FOOTPRINT 158
11.5.5 COMPANY REGIONAL FOOTPRINT 159
TABLE 161 COMPANY REGIONAL FOOTPRINT 159
TABLE 162 DIGITAL PHARMACY MARKET: DETAILED LIST OF KEY START-UPS/SMES 159
11.6 COMPETITIVE LEADERSHIP MAPPING 160
11.6.1 STARS 160
11.6.2 EMERGING LEADERS 160
11.6.3 PERVASIVE PLAYERS 160
11.6.4 PARTICIPANTS 160
FIGURE 25 DIGITAL PHARMACY MARKET (GLOBAL)
COMPANY EVALUATION MATRIX, 2021 161
11.7 COMPETITIVE LEADERSHIP MAPPING: START-UPS/SMES 162
11.7.1 PROGRESSIVE COMPANIES 162
11.7.2 STARTING BLOCKS 162
11.7.3 RESPONSIVE COMPANIES 162
11.7.4 DYNAMIC COMPANIES 162
FIGURE 26 COMPETITIVE LEADERSHIP MAPPING: START-UP/SME MATRIX MARKET 163
11.8 COMPETITIVE SITUATIONS AND TRENDS 164
11.8.1 PRODUCT/SERVICE UPGRADES 164
11.8.2 DEALS 165
11.8.3 OTHER DEVELOPMENTS 166
12 COMPANY PROFILES 167
12.1 KEY PLAYERS 167
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 CVS HEALTH 167
TABLE 163 CVS HEALTH: BUSINESS OVERVIEW 167
FIGURE 27 CVS HEALTH: COMPANY SNAPSHOT (2021) 168
12.1.2 CIGNA 170
TABLE 164 CIGNA: BUSINESS OVERVIEW 170
FIGURE 28 CIGNA: COMPANY SNAPSHOT (2021) 171
12.1.3 OPTUM, INC. (PART OF THE UNITEDHEALTH GROUP) 173
TABLE 165 OPTUM, INC.: BUSINESS OVERVIEW 173
FIGURE 29 OPTUM, INC.: COMPANY SNAPSHOT (2021) 174
12.1.4 WALGREEN CO. 176
TABLE 166 WALGREEN CO.: BUSINESS OVERVIEW 176
FIGURE 30 WALGREEN CO.: COMPANY SNAPSHOT (2021) 176
12.1.5 WALMART INC. 179
TABLE 167 WALMART INC.: BUSINESS OVERVIEW 179
FIGURE 31 WALMART INC.: COMPANY SNAPSHOT (2021) 180
12.1.6 THE KROGER CO. 182
TABLE 168 THE KROGER CO.: BUSINESS OVERVIEW 182
FIGURE 32 THE KROGER CO.: COMPANY SNAPSHOT (2020) 182
12.1.7 GIANT EAGLE, INC. 185
TABLE 169 GIANT EAGLE, INC.: BUSINESS OVERVIEW 185
12.1.8 AMAZON.COM, INC. 186
TABLE 170 AMAZON.COM, INC.: BUSINESS OVERVIEW 186
FIGURE 33 AMAZON.COM, INC.: COMPANY SNAPSHOT (2020) 187
12.1.9 PHARMEASY 190
TABLE 171 PHARMEASY: BUSINESS OVERVIEW 190
12.1.10 APEX PHARMACY 192
TABLE 172 APEX PHARMACY: BUSINESS OVERVIEW 192
12.1.11 APOLLO PHARMACY 194
TABLE 173 APOLLO PHARMACY: BUSINESS OVERVIEW 194
FIGURE 34 APOLLO HOSPITAL: COMPANY SNAPSHOT (2021) 195
12.1.12 RITE AID CORP 197
TABLE 174 RITE AID CORP.: BUSINESS OVERVIEW 197
FIGURE 35 RITE AID CORP.: COMPANY SNAPSHOT (2021) 197
12.1.13 COSTCO WHOLESALE CORPORATION 200
TABLE 175 COSTCO WHOLESALE CORPORATION: BUSINESS OVERVIEW 200
FIGURE 36 COSTCO WHOLESALE CORPORATION: COMPANY SNAPSHOT (2021) 200
12.2 OTHER KEY PLAYERS 203
12.2.1 SHOP-APOTHEKE.COM 203
12.2.2 NETMEDS.COM 204
12.2.3 DOCMORRIS 205
12.2.4 TATA 1MG 206
12.2.5 LLOYDSPHARMACY 207
12.2.6 GOODRX, INC. 208
12.2.7 HEALTHWAREHOUSE.COM 209
12.2.8 TELUS HEALTH 210
12.2.9 PHARMEX DIRECT INC. 210
12.2.10 HIMS & HERS HEALTH, INC. 211
12.2.11 RO PHARMACY 211
12.2.12 RX OUTREACH 212
12.2.13 THE INDEPENDENT PHARMACY 213
12.2.14 REXALL PHARMACY GROUP ULC 214
12.2.15 NORTHWESTPHARMACY.COM 215
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 217
13.1 DISCUSSION GUIDE 217
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 221
13.3 AVAILABLE CUSTOMIZATIONS 223
13.4 RELATED REPORTS 223
13.5 AUTHOR DETAILS 224

　

ページTOPに戻る


　

Summary

The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population.
However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period.

“Over-the-counter (OTC) productssegment isestimated to grow at the highest rate during the forecast period”
On the basis ofdrug type, the digital pharmacy market is segmented into prescription medicines and over-the-counter products. Prescription medicines accounted for the largest share of the global digital pharmacy market in 2021. The large share of this market segment can be attributed to factors such as growing prevalence of several chronic disorders and the subsequent growing demand for medications.
On the other hand, the over-the-counter (OTC) products segment isexpected to grow at the highest CAGR during the forecast period. Growth in this market segment is largely driven by the widespread availability and cost-effectiveness of over-the-counter products and the growing trend of self-medication.


“The Medicines & Treatmentssegment is expected to account for the largest share of theDigital Pharmacymarket in 2021”

On the basis ofproducts, the digital pharmacy market is segmented into medicines & treatments, personal care products, vitamins & supplements, and other products. The medicines & treatments segment accounted for the largest share of the global digital pharmacy market in 2021.
However, the vitamins & supplements segment is expected to register the highest CAGR during the forecast period due to increase prevalence of chronic diseases and the availability of multiple product options.



“Appssegment in the platformis expected to account for the largest share of the global digital pharmacy market”
On the basis ofplatforms, the digital pharmacy market is segmented into apps and websites. In 2021, apps is expected to hold the largest share of the global digital pharmacy market, growth in this segment is attributed to factors as the appsoffer lucrative promos or discounts to attract customers.The websitesplatform is estimated to grow at the second-highest CAGR during the forecast period due to convenience, privacy, and safety offered by websites are key factors driving the market growth.


“Captive segmentamong the business model accounted for the largest share of the global digital pharmacy market in 2021”

On the basis ofbusiness models, the digital pharmacy market is segmented into captive, franchise, and aggregator business models. The captive business model accounted for the largest share of the global digital pharmacy market in 2021 The captive business model is also estimated to register the highest CAGR during the forecast period. The flexibility, accessibility, and affordability of captive business models are key factors to segmental growth in the digital pharmacy market. The aggregator business model is estimated to grow at the second-highest CAGR during the forecast period.


“The Urbanareasaccounted for the largest share of the global digital pharmacy market in 2021”

On the basis ofgeographic coverage, the digital pharmacy market is segmented into urban and rural areas. Urban areas accounted for the largest share of the global digital pharmacy market in 2021 due to the growing penetration of the internet in urban areas.

“North America todominate the digital pharmacy market during forecast period”

North America accounted for the largest share of the digital pharmacy market in 2022. The growing prevalence of chronic conditions, the rising number of drug prescriptions resulting from the rapidly growing aging population, and the presence of key market players in the region are the key factors driving the growth of the digital pharmacy market in North America.
The Asia Pacific market is projected to register the highest CAGR during the forecast period, owing to the growing disease burden, growing patient population, and the rapidly growing pharmaceutical market.


Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (41%), Tier 2(31%), and Tier 3 (28%)
• By Designation: C-level (44%), Director-level (35%), and Others (21%)
• By Region: North America (46%), Europe (26%), Asia Pacific(18%),Latin America (7%) and Middle East & Africa (3%)

Prominent players in this market are CVS Health (US), Cigna (US), Optum, Inc. (Part of the UnitedHealth Group) (US), Walgreens Co. (US), Walmart Inc. (US), The Kroger Co. (US), Amazon.com, Inc. (US), GoodRx (US), Costco Wholesale Corporation (US), Rite Aid Corp. (US), Hims& Hers Health, Inc. (US), PharmEasy (India), Apollo Pharmacy (India), DocMorris (Netherlands), Giant Eagle Inc. (US), LloydsPharmacy (UK), Shop-apotheke.com (Netherlands), Tata 1mg (India), Netmeds.com (India), HealthWarehouse, Inc. (US), Pharmex Direct Inc. (Canada), Apex Pharmacy (UK), TELUS (Canada), RO Pharmacy (US), Rx Outreach (US), The Independent Pharmacy (UK), Rexall Pharmacy Group ULC (Canada), and NorthWestPharmacy.com (Canada).These players are increasingly focusing on product/service upgrades, acquisitions, partnerships, agreements, expansions, and collaborations to expand their product offerings in the digital pharmacy market.

Research Coverage
• The report studies theDigital Pharmacymarket based on drug type, products,platform,business model,geographic coverage, and region
• The report analyzes factors (such as drivers, restraints, opportunities, andchallenges) affecting the market growth
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders
• The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total digital pharmacy market
• The report forecasts the revenue of market segments with respect to five major regions

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the Digital Pharmacy market and provides them information on key market drivers, restraints, challenges, and opportunities.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.2.1 DIGITAL PHARMACY MARKET: INCLUSIONS & EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
FIGURE 1 DIGITAL PHARMACY MARKET 28
1.3.2 YEARS CONSIDERED FOR THE STUDY 29
1.4 CURRENCY 29
1.5 LIMITATIONS 29
1.5.1 SCOPE-RELATED LIMITATIONS 29
1.6 STAKEHOLDERS 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
FIGURE 2 RESEARCH DESIGN 30
2.1.1 SECONDARY DATA 31
2.1.1.1 Key data from secondary sources 32
2.1.2 PRIMARY RESEARCH 32
2.1.2.1 Key industry insights 33
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 34
2.2 MARKET ESTIMATION 34
2.2.1 APPROACH 1: SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 34
2.2.2 APPROACH: REVENUE MAPPING-BASED MARKET ESTIMATION 35
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 36
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36
FIGURE 6 REVENUE SHARE ANALYSIS ILLUSTRATION FOR CVS HEALTH 37
2.2.3 TOP-DOWN APPROACH: CONTRIBUTION-BASED MARKET SIZE ESTIMATION 38
FIGURE 7 DIGITAL PHARMACY MARKET: TOP-DOWN APPROACH 38
2.2.4 GROWTH FORECAST 38
FIGURE 8 IMPACT OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ON MARKET GROWTH & CAGR 39
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 39
2.3 MARKET DATA ESTIMATION AND TRIANGULATION 40
FIGURE 10 DATA TRIANGULATION METHODOLOGY 40
2.4 ASSUMPTIONS FOR THE STUDY 41
2.5 LIMITATIONS 41
2.6 RISK ASSESSMENT 42
TABLE 1 RISK ASSESSMENT: DIGITAL PHARMACY MARKET 42
3 EXECUTIVE SUMMARY 43
FIGURE 11 DIGITAL PHARMACY MARKET, BY DRUG TYPE, 2022 VS. 2027 (USD MILLION) 43
FIGURE 12 DIGITAL PHARMACY MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 44
FIGURE 13 DIGITAL PHARMACY MARKET, BY PLATFORM, 2022 VS. 2027 (USD MILLION) 44
FIGURE 14 DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2022 VS. 2027 (USD MILLION) 45
FIGURE 15 DIGITAL PHARMACY MARKET, BY GEOGRAPHIC COVERAGE,
2022 VS. 2027 (USD MILLION) 46
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE DIGITAL PHARMACY MARKET 47
4 PREMIUM INSIGHTS 48
4.1 DIGITAL PHARMACY MARKET OVERVIEW 48
FIGURE 17 GROWING GERIATRIC POPULATION TO DRIVE THE MARKET GROWTH 48
4.2 DIGITAL PHARMACY MARKET, BY PRODUCT 49
FIGURE 18 MEDICINES & TREATMENTS ACCOUNTED FOR THE LARGEST SHARE
OF THE DIGITAL PHARMACY MARKET IN 2021 49
4.3 NORTH AMERICA: DIGITAL PHARMACY MARKET, BY DRUG & COUNTRY (2021) 49
FIGURE 19 PRESCRIPTION MEDICINES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2021 49
4.4 GEOGRAPHICAL SNAPSHOT OF THE DIGITAL PHARMACY MARKET 50
FIGURE 20 ASIA PACIFIC MARKET TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 50
4.5 MARKET DYNAMICS 51
FIGURE 21 DIGITAL PHARMACY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 51
4.5.1 DRIVERS 52
4.5.1.1 Increasing consumer preference toward buying online medicines during and post the COVID-19 pandemic 52
TABLE 2 TOTAL NUMBER OF CONFIRMED CORONAVIRUS CASES, BY REGION
(AS OF JANUARY 7, 2022) 52
4.5.1.2 Consolidation in the market and partnerships 53
4.5.1.3 Growing geriatric population 53
TABLE 3 GLOBAL OVERVIEW OF THE RISE IN THE AGING POPULATION (MILLION) 53
4.5.2 RESTRAINTS 54
4.5.2.1 Growing number of illegal pharmacies 54
4.5.2.2 Risk of counterfeit drugs 54
4.5.2.3 Increased risk of drug abuse 55
4.5.3 OPPORTUNITIES 55
4.5.3.1 Emerging markets 55
4.5.3.2 Benefits of E-commerce 56
4.5.4 CHALLENGES 56
4.5.4.1 Challenges for patients relying on pharmacists for clinical support 56
4.5.4.2 Lack of strong national laws worldwide 57
4.5.4.3 Security and privacy concerns 58
4.6 VALUE CHAIN ANALYSIS 59
4.7 ECOSYSTEM ANALYSIS 60
4.8 PORTER’S FIVE FORCES ANALYSIS 60
TABLE 4 DIGITAL PHARMACY MARKET: PORTER’S FIVE FORCES ANALYSIS 60
4.8.1 INTENSITY OF COMPETITIVE RIVALRY 61
4.8.2 BARGAINING POWER OF SUPPLIERS 61
4.8.3 BARGAINING POWER OF BUYERS 61
4.8.4 THREAT FROM SUBSTITUTES 61
4.8.5 THREAT FROM NEW ENTRANTS 61
4.9 PRICING & REIMBURSEMENT ANALYSIS 61
TABLE 5 COMPARISON OF AVERAGE DISCOUNTED PRICES FOR A ONE-MONTH SUPPLY OF DRUGS 62
4.10 TECHNOLOGY ANALYSIS 62
4.10.1 MACHINE LEARNING 62
4.10.2 INTERNET OF THINGS 63
4.10.3 BLOCKCHAIN 63
4.10.4 CLOUD COMPUTING 63
4.11 INDUSTRY TRENDS 63
4.11.1 ONLINE PRESCRIPTION REFILL 63
4.11.2 VIRTUAL HEALTHCARE SERVICES 64
4.11.3 DIGITAL HEALTH DIAGNOSTIC TOOLS 64
4.12 KEY CONFERENCES & EVENTS IN 2021–2022 65
4.13 REGULATORY ANALYSIS 65
4.13.1 NORTH AMERICA 65
4.13.1.1 US 65
4.13.1.2 Canada 66
4.13.2 EUROPE 66
4.13.3 ASIA PACIFIC 67
4.13.4 REST OF THE WORLD 67
TABLE 6 APPROACHES OF REGULATORY AUTHORITIES (RA) WORLDWIDE
TO CONTROL MEDICINAL PRODUCT ONLINE SALES 67
4.14 CASE STUDIES 68
4.14.1 MAGENTO 2 WEB APP MODERNIZATION 68
4.14.1.1 Use Case 1: Need to Revamp Online Store 68
4.14.2 WALMART REACT NATIVE PHARMACY 69
4.14.2.1 Use Case 2: Need to Rebuild Pharmacy App 69
4.15 IMPACT OF COVID-19 ON THE DIGITAL PHARMACY MARKET 69
 
5 DIGITAL PHARMACY MARKET, BY DRUG TYPE 70
5.1 INTRODUCTION 71
TABLE 7 DIGITAL PHARMACY MARKET, BY DRUG TYPE, 2020–2027 (USD MILLION) 71
5.2 PRESCRIPTION MEDICINES 71
5.2.1 GROWING GERIATRIC POPULATION AND SUBSEQUENT INCREASE IN CHRONIC DISEASES TO DRIVE THE DEMAND FOR PRESCRIPTION MEDICATION 71
TABLE 8 DIGITAL PHARMACY MARKET FOR PRESCRIPTION MEDICINES, BY REGION, 2020–2027 (USD MILLION) 72
TABLE 9 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR PRESCRIPTION MEDICINES, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 10 EUROPE: DIGITAL PHARMACY MARKET FOR PRESCRIPTION MEDICINES,
BY COUNTRY, 2020–2027 (USD MILLION) 73
5.3 OVER-THE-COUNTER PRODUCTS 73
5.3.1 EASE OF USE AND CONVENIENCE ASSOCIATED WITH OVER-THE-COUNTER PRODUCTS TO DRIVE MARKET GROWTH 73
TABLE 11 DIGITAL PHARMACY MARKET FOR OVER-THE-COUNTER PRODUCTS,
BY REGION, 2020–2027 (USD MILLION) 74
TABLE 12 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR OVER-THE-COUNTER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 74
TABLE 13 EUROPE: DIGITAL PHARMACY MARKET FOR OVER-THE-COUNTER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 75
6 DIGITAL PHARMACY MARKET, BY PRODUCT 76
6.1 INTRODUCTION 77
TABLE 14 DIGITAL PHARMACY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 77
6.2 MEDICINES & TREATMENTS 77
TABLE 15 DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY REGION, 2020–2027 (USD MILLION) 78
TABLE 16 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 17 EUROPE: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 18 ASIA PACIFIC: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 19 DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY TYPE, 2020–2027 (USD MILLION) 79
6.2.1 DIABETES CARE 79
6.2.1.1 Growing global diabetic population will ensure strong demand for diabetes care medicines & treatments 79
TABLE 20 DIGITAL PHARMACY MARKET FOR DIABETES CARE MEDICINES & TREATMENTS, BY REGION, 2020–2027 (USD MILLION) 80
6.2.2 HEART CARE 80
6.2.2.1 Rising incidence of cardiovascular diseases drives the demand for heart care medicines & treatments 80
TABLE 21 DIGITAL PHARMACY MARKET FOR HEART CARE MEDICINES & TREATMENTS, BY REGION, 2020–2027 (USD MILLION) 81
6.2.3 ONCOLOGY 81
6.2.3.1 Increasing prevalence of cancer is a major factor driving the growth of this market segment 81
TABLE 22 DIGITAL PHARMACY MARKET FOR ONCOLOGY MEDICINES & TREATMENTS, BY REGION, 2020–2027 (USD MILLION) 81
6.2.3.2 Other medicines & treatments 82
TABLE 23 DIGITAL PHARMACY MARKET FOR OTHER MEDICINES & TREATMENTS,
BY REGION, 2020–2027 (USD MILLION) 82
6.3 PERSONAL CARE PRODUCTS 82
6.3.1 GROWING FOCUS ON PERSONAL HEALTH & HYGIENE TO DRIVE MARKET GROWTH 82
TABLE 24 DIGITAL PHARMACY MARKET FOR PERSONAL CARE PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 25 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR PERSONAL CARE PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 26 EUROPE: DIGITAL PHARMACY MARKET FOR PERSONAL CARE PRODUCTS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 27 ASIA PACIFIC: DIGITAL PHARMACY MARKET FOR PERSONAL CARE PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 VITAMINS & SUPPLEMENTS 84
6.4.1 GROWING DEMAND FOR IMMUNITY-ASSOCIATED SUPPLEMENTS IN THE WAKE OF THE COVID-19 PANDEMIC TO DRIVE MARKET GROWTH 84
TABLE 28 DIGITAL PHARMACY MARKET FOR VITAMINS & SUPPLEMENTS, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 29 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR VITAMINS & SUPPLEMENTS, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 30 EUROPE: DIGITAL PHARMACY MARKET FOR VITAMINS & SUPPLEMENTS,
BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 31 ASIA PACIFIC: DIGITAL PHARMACY MARKET FOR VITAMINS & SUPPLEMENTS, BY COUNTRY, 2020–2027 (USD MILLION) 86
6.5 OTHER PRODUCTS 86
TABLE 32 DIGITAL PHARMACY MARKET FOR OTHER PRODUCTS, BY REGION,
2020–2027 (USD MILLION) 86
TABLE 33 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 34 EUROPE: DIGITAL PHARMACY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 35 ASIA PACIFIC: DIGITAL PHARMACY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2020–2027 (USD MILLION) 87
7 DIGITAL PHARMACY MARKET, BY PLATFORM 88
7.1 INTRODUCTION 89
TABLE 36 DIGITAL PHARMACY MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 89
7.2 APPS 89
7.2.1 ADVANTAGES SUCH AS CONTACTLESS DELIVERY WILL
DRIVE THE DEMAND FOR APPS 89
TABLE 37 DIGITAL PHARMACY APPS MARKET, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 38 NORTH AMERICA: DIGITAL PHARMACY APPS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 90
TABLE 39 EUROPE: DIGITAL PHARMACY APPS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 90
TABLE 40 ASIA PACIFIC: DIGITAL PHARMACY APPS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 91
7.3 WEBSITES 91
7.3.1 PROMOTIONS, DISCOUNTS, AND OFFERS PROVIDED BY WEBSITES TO DRIVE MARKET GROWTH 91
TABLE 41 DIGITAL PHARMACY WEBSITES MARKET, BY REGION,
2020–2027 (USD MILLION) 92
TABLE 42 NORTH AMERICA: DIGITAL PHARMACY WEBSITES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 43 EUROPE: DIGITAL PHARMACY WEBSITES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 92
TABLE 44 ASIA PACIFIC: DIGITAL PHARMACY WEBSITES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 93
8 DIGITAL PHARMACY MARKET, BY BUSINESS MODEL 94
8.1 INTRODUCTION 95
TABLE 45 DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 95
8.2 CAPTIVE 95
8.2.1 FLEXIBILITY, ACCESSIBILITY, AND AFFORDABILITY OF CAPTIVE MODELS—
KEY FACTORS DRIVING MARKET GROWTH 95
TABLE 46 DIGITAL PHARMACY MARKET FOR CAPTIVE MODELS, BY REGION, 2020–2027 (USD MILLION) 96
TABLE 47 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR CAPTIVE MODELS,
BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 48 EUROPE: DIGITAL PHARMACY MARKET FOR CAPTIVE MODELS, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 49 ASIA PACIFIC: DIGITAL PHARMACY MARKET FOR CAPTIVE MODELS,
BY COUNTRY, 2020–2027 (USD MILLION) 97
8.3 FRANCHISE 97
8.3.1 GROWING NUMBER OF PHARMACY FRANCHISES TO DRIVE MARKET GROWTH 97
TABLE 50 DIGITAL PHARMACY MARKET FOR FRANCHISE MODELS, BY REGION,
2020–2027 (USD MILLION) 98
TABLE 51 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR FRANCHISE MODELS,
BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 52 EUROPE: DIGITAL PHARMACY MARKET FOR FRANCHISE MODELS,
BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 53 ASIA PACIFIC: DIGITAL PHARMACY MARKET FOR FRANCHISE MODELS,
BY COUNTRY, 2020–2027 (USD MILLION) 99
8.4 AGGREGATOR 99
8.4.1 QUALITY SERVICES ASSOCIATED WITH AGGREGATOR MODELS TO DRIVE MARKET GROWTH 99
TABLE 54 DIGITAL PHARMACY MARKET FOR AGGREGATOR MODELS, BY REGION, 2020–2027 (USD MILLION) 100
TABLE 55 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR AGGREGATOR MODELS, BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 56 EUROPE: DIGITAL PHARMACY MARKET FOR AGGREGATOR MODELS,
BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 57 ASIA PACIFIC: DIGITAL PHARMACY MARKET FOR AGGREGATOR MODELS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
9 DIGITAL PHARMACY MARKET, BY GEOGRAPHIC COVERAGE 102
9.1 INTRODUCTION 103
TABLE 58 DIGITAL PHARMACY MARKET, BY GEOGRAPHIC COVERAGE,
2020–2027 (USD MILLION) 103
9.2 URBAN AREAS 103
9.2.1 RAPID INTERNET PENETRATION IN URBAN AREAS TO DRIVE MARKET GROWTH IN THIS SEGMENT 103
TABLE 59 DIGITAL PHARMACY MARKET IN URBAN AREAS, BY REGION,
2020–2027 (USD MILLION) 104
9.3 RURAL AREAS 104
9.3.1 GOVERNMENT INITIATIVES TO FUEL THE DEMAND FOR DIGITAL PHARMACIES IN RURAL AREAS 104
TABLE 60 DIGITAL PHARMACY MARKET IN RURAL AREAS, BY REGION,
2020–2027 (USD MILLION) 105
10 DIGITAL PHARMACY MARKET, BY REGION 106
10.1 INTRODUCTION 107
TABLE 61 DIGITAL PHARMACY MARKET, BY REGION, 2020–2027 (USD MILLION) 107
10.2 NORTH AMERICA 107
10.2.1 IMPACT OF COVID-19 ON THE NORTH AMERICAN DIGITAL
PHARMACY MARKET 107
FIGURE 22 NORTH AMERICA: DIGITAL PHARMACY MARKET SNAPSHOT 108
TABLE 62 NORTH AMERICA: DIGITAL PHARMACY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 109
TABLE 63 NORTH AMERICA: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 109
TABLE 64 NORTH AMERICA: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 109
TABLE 65 NORTH AMERICA: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY TYPE, 2020–2027 (USD MILLION) 110
TABLE 66 NORTH AMERICA: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 110
TABLE 67 NORTH AMERICA: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL, 2020–2027 (USD MILLION) 110
TABLE 68 NORTH AMERICA: DIGITAL PHARMACY MARKET, BY GEOGRAPHIC COVERAGE, 2020–2027 (USD MILLION) 111
10.2.2 US 111
10.2.2.1 The US is the largest regional market for digital pharmacy, mainly due to the rising prevalence of chronic conditions and the growing number of prescriptions 111
TABLE 69 US: KEY MACROINDICATORS 112
TABLE 70 US: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 112
TABLE 71 US: DIGITAL PHARMACY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 112
TABLE 72 US: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY TYPE, 2020–2027 (USD MILLION) 113
TABLE 73 US: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 113
TABLE 74 US: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 113
TABLE 75 US: DIGITAL PHARMACY MARKET, BY GEOGRAPHIC COVERAGE,
2020–2027 (USD MILLION) 114
10.2.3 CANADA 114
10.2.3.1 Rising drug expenditures to propel market growth in Canada 114
TABLE 76 CANADA: KEY MACROINDICATORS 115
TABLE 77 CANADA: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 115
TABLE 78 CANADA: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 116
TABLE 79 CANADA: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 80 CANADA: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 116
TABLE 81 CANADA: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 117
TABLE 82 CANADA: DIGITAL PHARMACY MARKET, BY GEOGRAPHIC COVERAGE,
2020–2027 (USD MILLION) 117
10.3 EUROPE 117
10.3.1 IMPACT OF COVID-19 ON THE EUROPEAN DIGITAL PHARMACY MARKET 118
TABLE 83 EUROPE: DIGITAL PHARMACY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 118
TABLE 84 EUROPE: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 118
TABLE 85 EUROPE: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 119
TABLE 86 EUROPE: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY TYPE, 2020–2027 (USD MILLION) 119
TABLE 87 EUROPE: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 119
TABLE 88 EUROPE: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 120
10.3.2 GERMANY 120
10.3.2.1 Germany is the fastest-growing market for digital pharmacies in Europe 120
TABLE 89 GERMANY: KEY MACROINDICATORS 121
TABLE 90 GERMANY: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 121
TABLE 91 GERMANY: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 121
TABLE 92 GERMANY: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY TYPE, 2020–2027 (USD MILLION) 122
TABLE 93 GERMANY: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 122
TABLE 94 GERMANY: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 122
10.3.3 UK 123
10.3.3.1 Rising initiatives to improve the safety of digital pharmacies to boost the market growth 123
TABLE 95 UK: KEY MACROINDICATORS 124
TABLE 96 UK: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 124
TABLE 97 UK: DIGITAL PHARMACY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 124
TABLE 98 UK: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 99 UK: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 125
TABLE 100 UK: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 125
10.3.4 FRANCE 126
10.3.4.1 Rising geriatric population in the country to support market growth 126
TABLE 101 FRANCE: KEY MACROINDICATORS 126
TABLE 102 FRANCE: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 126
TABLE 103 FRANCE: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 127
TABLE 104 FRANCE: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 105 FRANCE: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 127
TABLE 106 FRANCE: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 128
10.3.5 ITALY 128
10.3.5.1 Growing burden of chronic diseases is driving the market
growth in Italy 128
TABLE 107 ITALY: KEY MACROINDICATORS 129
TABLE 108 ITALY: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 129
TABLE 109 ITALY: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 129
TABLE 110 ITALY: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 111 ITALY: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 130
TABLE 112 ITALY: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 130
10.3.6 SPAIN 131
10.3.6.1 Increasing focus on improving the healthcare infrastructure in the country to support market growth 131
TABLE 113 SPAIN: KEY MACROINDICATORS 131
TABLE 114 SPAIN: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 132
TABLE 115 SPAIN: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 132
TABLE 116 SPAIN: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 117 SPAIN: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 133
TABLE 118 SPAIN: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 133
10.3.7 ROE 133
TABLE 119 ROE: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 134
TABLE 120 ROE: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 134
TABLE 121 ROE: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY TYPE, 2020–2027 (USD MILLION) 135
TABLE 122 ROE: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 135
TABLE 123 ROE: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 135
10.4 ASIA PACIFIC 136
10.4.1 IMPACT OF COVID-19 ON THE ASIA PACIFIC DIGITAL PHARMACY MARKET 136
FIGURE 23 ASIA PACIFIC: DIGITAL PHARMACY MARKET SNAPSHOT 137
TABLE 124 ASIA PACIFIC: DIGITAL PHARMACY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 138
TABLE 125 ASIA PACIFIC: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 138
TABLE 126 ASIA PACIFIC: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 138
TABLE 127 ASIA PACIFIC: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 139
10.4.2 CHINA 139
10.4.2.1 Increasing consumer demand for OTC products to drive the market for digital pharmacy in China 139
TABLE 128 CHINA: KEY MACROINDICATORS 140
TABLE 129 CHINA: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 140
TABLE 130 CHINA: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 140
TABLE 131 CHINA: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 141
10.4.3 JAPAN 141
10.4.3.1 Rising healthcare expenditures and the growing burden of non-communicable diseases (NCDs) to drive market growth in Japan 141
TABLE 132 JAPAN: KEY MACROINDICATORS 142
TABLE 133 JAPAN: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 142
TABLE 134 JAPAN: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 142
TABLE 135 JAPAN: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 143
10.4.4 INDIA 143
10.4.4.1 Favorable government initiatives and high density of rural population to support market growth in India 143
TABLE 136 INDIA: KEY MACROINDICATORS 144
TABLE 137 INDIA: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 144
TABLE 138 INDIA: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 144
TABLE 139 INDIA: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS,
BY TYPE, 2020–2027 (USD MILLION) 145
TABLE 140 INDIA: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 145
TABLE 141 INDIA: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 145
10.4.5 REST OF ASIA PACIFIC 146
TABLE 142 ROAPAC: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 146
TABLE 143 ROAPAC: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 147
TABLE 144 ROAPAC: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 147
TABLE 145 ROAPAC: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 147
10.5 LATIN AMERICA 148
10.5.1 GROWING INTERNET USERS WILL FAVOR MARKET GROWTH IN LATAM 148
10.5.1.1 Impact of COVID-19 on the Latin American digital pharmacy market 148
TABLE 146 LATIN AMERICA: KEY MACROINDICATORS 149
TABLE 147 LATIN AMERICA: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 149
TABLE 148 LATIN AMERICA: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 149
TABLE 149 LATIN AMERICA: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 150 LATIN AMERICA: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 150
TABLE 151 LATIN AMERICA: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 150
10.6 MIDDLE EAST & AFRICA 151
10.6.1 INCREASING DEMAND FOR ONLINE PHARMACEUTICAL PRODUCTS WILL DRIVE THE MARKET IN THE MEA 151
10.6.1.1 Impact of COVID-19 on the Middle East & Africa digital
pharmacy market 152
TABLE 152 MEA: DIGITAL PHARMACY MARKET, BY DRUG TYPE,
2020–2027 (USD MILLION) 152
TABLE 153 MEA: DIGITAL PHARMACY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 152
TABLE 154 MEA: DIGITAL PHARMACY MARKET FOR MEDICINES & TREATMENTS, BY TYPE, 2020–2027 (USD MILLION) 153
TABLE 155 MEA: DIGITAL PHARMACY MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 153
TABLE 156 MEA: DIGITAL PHARMACY MARKET, BY BUSINESS MODEL,
2020–2027 (USD MILLION) 153
11 COMPETITIVE LANDSCAPE 154
11.1 OVERVIEW 154
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 154
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN
THE DIGITAL PHARMACY MARKET 154
11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 155
11.4 MARKET RANKING 156
FIGURE 24 US DIGITAL PHARMACY MARKET RANKING, BY KEY PLAYER, 2021 156
11.5 COMPETITIVE BENCHMARKING 157
11.5.1 OVERALL COMPANY FOOTPRINT 157
TABLE 157 OVERALL COMPANY FOOTPRINT 157
11.5.2 COMPANY DRUG TYPE FOOTPRINT 157
TABLE 158 COMPANY DRUG TYPE FOOTPRINT 157
11.5.3 COMPANY PRODUCT FOOTPRINT 158
TABLE 159 COMPANY PRODUCT FOOTPRINT 158
11.5.4 COMPANY PLATFORM FOOTPRINT 158
TABLE 160 COMPANY PLATFORM FOOTPRINT 158
11.5.5 COMPANY REGIONAL FOOTPRINT 159
TABLE 161 COMPANY REGIONAL FOOTPRINT 159
TABLE 162 DIGITAL PHARMACY MARKET: DETAILED LIST OF KEY START-UPS/SMES 159
11.6 COMPETITIVE LEADERSHIP MAPPING 160
11.6.1 STARS 160
11.6.2 EMERGING LEADERS 160
11.6.3 PERVASIVE PLAYERS 160
11.6.4 PARTICIPANTS 160
FIGURE 25 DIGITAL PHARMACY MARKET (GLOBAL)
COMPANY EVALUATION MATRIX, 2021 161
11.7 COMPETITIVE LEADERSHIP MAPPING: START-UPS/SMES 162
11.7.1 PROGRESSIVE COMPANIES 162
11.7.2 STARTING BLOCKS 162
11.7.3 RESPONSIVE COMPANIES 162
11.7.4 DYNAMIC COMPANIES 162
FIGURE 26 COMPETITIVE LEADERSHIP MAPPING: START-UP/SME MATRIX MARKET 163
11.8 COMPETITIVE SITUATIONS AND TRENDS 164
11.8.1 PRODUCT/SERVICE UPGRADES 164
11.8.2 DEALS 165
11.8.3 OTHER DEVELOPMENTS 166
12 COMPANY PROFILES 167
12.1 KEY PLAYERS 167
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 CVS HEALTH 167
TABLE 163 CVS HEALTH: BUSINESS OVERVIEW 167
FIGURE 27 CVS HEALTH: COMPANY SNAPSHOT (2021) 168
12.1.2 CIGNA 170
TABLE 164 CIGNA: BUSINESS OVERVIEW 170
FIGURE 28 CIGNA: COMPANY SNAPSHOT (2021) 171
12.1.3 OPTUM, INC. (PART OF THE UNITEDHEALTH GROUP) 173
TABLE 165 OPTUM, INC.: BUSINESS OVERVIEW 173
FIGURE 29 OPTUM, INC.: COMPANY SNAPSHOT (2021) 174
12.1.4 WALGREEN CO. 176
TABLE 166 WALGREEN CO.: BUSINESS OVERVIEW 176
FIGURE 30 WALGREEN CO.: COMPANY SNAPSHOT (2021) 176
12.1.5 WALMART INC. 179
TABLE 167 WALMART INC.: BUSINESS OVERVIEW 179
FIGURE 31 WALMART INC.: COMPANY SNAPSHOT (2021) 180
12.1.6 THE KROGER CO. 182
TABLE 168 THE KROGER CO.: BUSINESS OVERVIEW 182
FIGURE 32 THE KROGER CO.: COMPANY SNAPSHOT (2020) 182
12.1.7 GIANT EAGLE, INC. 185
TABLE 169 GIANT EAGLE, INC.: BUSINESS OVERVIEW 185
12.1.8 AMAZON.COM, INC. 186
TABLE 170 AMAZON.COM, INC.: BUSINESS OVERVIEW 186
FIGURE 33 AMAZON.COM, INC.: COMPANY SNAPSHOT (2020) 187
12.1.9 PHARMEASY 190
TABLE 171 PHARMEASY: BUSINESS OVERVIEW 190
12.1.10 APEX PHARMACY 192
TABLE 172 APEX PHARMACY: BUSINESS OVERVIEW 192
12.1.11 APOLLO PHARMACY 194
TABLE 173 APOLLO PHARMACY: BUSINESS OVERVIEW 194
FIGURE 34 APOLLO HOSPITAL: COMPANY SNAPSHOT (2021) 195
12.1.12 RITE AID CORP 197
TABLE 174 RITE AID CORP.: BUSINESS OVERVIEW 197
FIGURE 35 RITE AID CORP.: COMPANY SNAPSHOT (2021) 197
12.1.13 COSTCO WHOLESALE CORPORATION 200
TABLE 175 COSTCO WHOLESALE CORPORATION: BUSINESS OVERVIEW 200
FIGURE 36 COSTCO WHOLESALE CORPORATION: COMPANY SNAPSHOT (2021) 200
12.2 OTHER KEY PLAYERS 203
12.2.1 SHOP-APOTHEKE.COM 203
12.2.2 NETMEDS.COM 204
12.2.3 DOCMORRIS 205
12.2.4 TATA 1MG 206
12.2.5 LLOYDSPHARMACY 207
12.2.6 GOODRX, INC. 208
12.2.7 HEALTHWAREHOUSE.COM 209
12.2.8 TELUS HEALTH 210
12.2.9 PHARMEX DIRECT INC. 210
12.2.10 HIMS & HERS HEALTH, INC. 211
12.2.11 RO PHARMACY 211
12.2.12 RX OUTREACH 212
12.2.13 THE INDEPENDENT PHARMACY 213
12.2.14 REXALL PHARMACY GROUP ULC 214
12.2.15 NORTHWESTPHARMACY.COM 215
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 217
13.1 DISCUSSION GUIDE 217
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 221
13.3 AVAILABLE CUSTOMIZATIONS 223
13.4 RELATED REPORTS 223
13.5 AUTHOR DETAILS 224

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（apps）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/08　10:26

154.13 円

166.76 円

202.76 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.